The chip removes cells, which could become tumours, before they are implanted in a patient
News
Royal Marsden to implement RaySearch’s online adaptive radiation therapy system
OART is increasingly emerging to assess and adapt treatment for cancer patients
Researchers identify new treatment target for genetic epilepsy
The rare neurodevelopmental condition CDKL5 is characterised by early-onset epilepsy
JCVI announces advice for 2024 spring COVID-19 vaccine programme
The committee has advised that the vaccine should be given to those at the highest risk
Researchers discover new type of memory B cell that remembers allergies
The cell could be a target for new immunotherapies for the chronic disease
Brainomix’s AI-enabled stroke software endorsed by NICE
The HTA reported that Brainomix 360 improved access to treatment for stroke patients
ALTURiX acquires exclusive UK rights to three new products
The new products are in the areas of gastrointestinal and respiratory medicines
New heart treatment to help grow replacement heart valves in the body
The biodegradable polymer scaffold encourages the body to grow new tissue
Study reveals blood test can pinpoint cause of brain injury in newborns
Hypoxic-ischaemic encephalopathy affects around three million babies worldwide every year
New programme shown to help dementia patients live independently
The neurodegenerative condition currently affects over 944,000 people in the UK
Study reveals AI can predict patients’ survival in glioblastoma
The aggressive brain cancer is responsible for over 3,000 cases in the UK every year
Study reveals SARS-CoV-2 can infect dopamine neurons causing senescence
Dopamine neuron senescence is a hallmark of Parkinson’s disease
NHS launches BRCA testing programme for people of Jewish descent
Individuals with Jewish ancestry are six times more likely to carry a genetic fault
Millions of people to view digital prescriptions via the NHS app
Prescriptions ordered via the app are expected to save around 1.85 million hours in 2024
Cancer treatment could identify patients most likely to respond to cancer drugs
Tumours with high mtDNA mutations more likely to respond to Opdivo
